Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma

Cancer cells escape immune recognition by exploiting the programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) immune checkpoint axis. Immune checkpoint inhibitors that target PD-1/PD-L1 unleash the properties of effector T cells that are licensed to kill cancer cells. Immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Apostolidis, John, Sayyed, Ayman, Darweesh, Mohammed, Kaloyannidis, Panayotis, Al Hashmi, Hani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647776/
https://www.ncbi.nlm.nih.gov/pubmed/33178841
http://dx.doi.org/10.1155/2020/9350272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647776/
https://www.ncbi.nlm.nih.gov/pubmed/33178841
http://dx.doi.org/10.1155/2020/9350272

Ejemplares similares